Neurogene
NGNE
NASDAQ
IPO2023
about NGNE
Neurogene specializes in developing gene therapies for inherited retinal diseases, with a focus on treatments for geographic atrophy and wet age-related macular degeneration.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $19.84 | $20.00 | $18.83 | $311.19M | 295.20K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.99 | n/a | n/a | 0% | 0% | 0% |